Abstract
Method: Patients with measurable advanced gastric cancer, refractory to prior chemotherapy were eligible for study. Cisplatin 20mg/m^2/d, 5-FU 800mg/m^2/d and leucovorin 90mg/m^2/d were administered simultaneously by continuous 96-hour intravenous infusion every three weeks. Patients were evaluated for response, survival, and toxicity.
Results: Twenty patients were studied. Fifteen patients were evaluable. There were no complete response. Partial response was achieved in 4 patients. The response rate of PFL chemotherapy were 27%. The overall toxicity was tolerable. Mucositis and leukopenia were the major toxicities. No grade IV toxicities or treatment-related deaths occurred.
Conclusions: PEL chemotherpy is safe and may be effective in the treatment of refractory gastric cancer patients. Further clinical studies of PFL in gastric cancer may be indicated.
| Original language | English |
|---|---|
| Pages (from-to) | 255-262 |
| Number of pages | 8 |
| Journal | 放射治療與腫瘤學 |
| Volume | 1 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - 1994 |
| Externally published | Yes |
Fingerprint
Keywords
- Cisplatin
- 5-Fluorouracil
- Leucovorin頑固性胃癌
- Refractory Gastric Cancer
- Fluorouracil
- Leucovorin
Cite this
Cisplain, 5-Fluorouracil (5-FU), and Leucovorin(LV) in Refractory Gastric Cancer Patients. / 陳榮楷(Wing-K. Chan); 吳秋文(Chu W. Wu); 林增熙(Tzeng H. Lin); 季匡華(Kwan H. Chi); 趙毅(Yee Chao); 黃以信(Y. S. Huang); 吳銘芳(Ming F. Wu); 陳育民(Yue M. Chen); 劉敏(Ming Liu); 彭汪嘉康(Jacqueline Whang-Peng); 李壽東(Shou D. Lee); 雷永耀(Wing Y. Lui).
In: 放射治療與腫瘤學, Vol. 1, No. 3, 1994, p. 255-262.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Cisplain, 5-Fluorouracil (5-FU), and Leucovorin(LV) in Refractory Gastric Cancer Patients
AU - 陳, 榮楷(Wing-K. Chan)
AU - 吳, 秋文(Chu W. Wu)
AU - 林, 增熙(Tzeng H. Lin)
AU - 季, 匡華(Kwan H. Chi)
AU - 趙, 毅(Yee Chao)
AU - 黃, 以信(Y. S. Huang)
AU - 吳, 銘芳(Ming F. Wu)
AU - 陳, 育民(Yue M. Chen)
AU - 劉, 敏(Ming Liu)
AU - 彭汪, 嘉康(Jacqueline Whang-Peng)
AU - 李, 壽東(Shou D. Lee)
AU - 雷, 永耀(Wing Y. Lui)
PY - 1994
Y1 - 1994
N2 - Background: Patients with advanced gastric cancer who failed first line chemotherapy have a poor prognosis. However, there are few effective treatments against refractory gastric cancer. Based on encouraging results of cisplatin, 5-Fluorouracil and leucovorin (PFL) in patients with gastric cancer, nasopharyngeal cancer and other cancers, we conducted this pilot study of test PEL chemotherapy in patients with refractory advanced gastric cancer.Method: Patients with measurable advanced gastric cancer, refractory to prior chemotherapy were eligible for study. Cisplatin 20mg/m^2/d, 5-FU 800mg/m^2/d and leucovorin 90mg/m^2/d were administered simultaneously by continuous 96-hour intravenous infusion every three weeks. Patients were evaluated for response, survival, and toxicity.Results: Twenty patients were studied. Fifteen patients were evaluable. There were no complete response. Partial response was achieved in 4 patients. The response rate of PFL chemotherapy were 27%. The overall toxicity was tolerable. Mucositis and leukopenia were the major toxicities. No grade IV toxicities or treatment-related deaths occurred.Conclusions: PEL chemotherpy is safe and may be effective in the treatment of refractory gastric cancer patients. Further clinical studies of PFL in gastric cancer may be indicated.
AB - Background: Patients with advanced gastric cancer who failed first line chemotherapy have a poor prognosis. However, there are few effective treatments against refractory gastric cancer. Based on encouraging results of cisplatin, 5-Fluorouracil and leucovorin (PFL) in patients with gastric cancer, nasopharyngeal cancer and other cancers, we conducted this pilot study of test PEL chemotherapy in patients with refractory advanced gastric cancer.Method: Patients with measurable advanced gastric cancer, refractory to prior chemotherapy were eligible for study. Cisplatin 20mg/m^2/d, 5-FU 800mg/m^2/d and leucovorin 90mg/m^2/d were administered simultaneously by continuous 96-hour intravenous infusion every three weeks. Patients were evaluated for response, survival, and toxicity.Results: Twenty patients were studied. Fifteen patients were evaluable. There were no complete response. Partial response was achieved in 4 patients. The response rate of PFL chemotherapy were 27%. The overall toxicity was tolerable. Mucositis and leukopenia were the major toxicities. No grade IV toxicities or treatment-related deaths occurred.Conclusions: PEL chemotherpy is safe and may be effective in the treatment of refractory gastric cancer patients. Further clinical studies of PFL in gastric cancer may be indicated.
KW - Cisplatin
KW - 5-Fluorouracil
KW - Leucovorin頑固性胃癌
KW - Refractory Gastric Cancer
KW - Fluorouracil
KW - Leucovorin
U2 - 10.6316/TRO/199401
DO - 10.6316/TRO/199401
M3 - Article
VL - 1
SP - 255
EP - 262
JO - 放射治療與腫瘤學
JF - 放射治療與腫瘤學
SN - 1023-988x
IS - 3
ER -